What is Eton Pharmaceuticals' operating income?

Eton Pharmaceuticals' total operating income in 2025 was -$844 thousand, based on the following breakdown: Total Gross Profit: $42.74 million Total Operating Expenses: $43.58 million

Eton Pharmaceuticals (ETON) Financials

$55.21 +0.46 (+0.84%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$55.90 +0.69 (+1.24%)

As of 10/9/2026 07:50 PM Eastern

Compare

Annual Income Statements for Eton Pharmaceuticals

This table shows Eton Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-37	-18	-28	-1.96	-9.02	-0.94	-3.82	-4.60
Consolidated Net Income / (Loss)	-13	-18	-28	-1.96	-9.02	-0.94	-3.82	-4.60
Net Income / (Loss) Continuing Operations	-13	-18	-28	-1.96	-9.02	-0.94	-3.82	-4.60
Total Pre-Tax Income	-13	-18	-28	-1.96	-9.02	-0.69	-3.81	-4.56
Total Operating Income	-10	-19	-27	-1.50	-8.26	-1.19	-2.60	-0.84
Total Gross Profit	0.00	0.51	-0.40	19	14	21	23	43
Total Revenue	0.00	0.96	0.04	22	21	32	39	80
Operating Revenue	0.00	0.96	0.04	22	21	32	39	80
Total Cost of Revenue	0.00	0.45	0.44	2.83	6.93	11	16	37
Operating Cost of Revenue	0.00	0.45	0.44	2.83	6.93	11	16	37
Total Operating Expenses	10	19	27	21	23	22	26	44
Selling, General & Admin Expense	4.69	7.55	13	14	19	19	23	36
Research & Development Expense	5.63	12	14	6.24	4.00	3.32	3.26	7.77
Total Other Income / (Expense), net	-2.42	0.28	-0.86	-0.46	-0.76	0.50	-1.21	-3.71
Other Income / (Expense), net	-2.42	0.28	-0.86	-0.83	-0.76	0.50	-1.21	-3.71
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.25	0.02	0.04
Basic Earnings per Share	($5.80)	($1.03)	($1.33)	($0.08)	($0.36)	($0.04)	($0.15)	($0.17)
Weighted Average Basic Shares Outstanding	6.42M	17.76M	21.01M	25.21M	25.15M	25.65M	25.90M	26.91M
Weighted Average Diluted Shares Outstanding	6.42M	17.76M	21.01M	25.21M	25.46M	25.69M	26.82M	27.28M
Weighted Average Basic & Diluted Shares Outstanding	6.42M	17.76M	21.01M	25.21M	25.46M	25.69M	26.82M	27.28M

This table shows Eton Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-2.26	-0.81	-3.04	0.63	-0.60	-1.57	-2.59	-1.93	1.48	1.55	12
Consolidated Net Income / (Loss)	-2.26	-0.81	-3.04	0.63	-0.60	-1.57	-2.59	-1.93	1.48	1.55	12
Net Income / (Loss) Continuing Operations	-2.26	-0.81	-3.04	0.63	-0.60	-1.57	-2.59	-1.93	1.48	1.55	12
Total Pre-Tax Income	-2.01	-0.81	-2.99	0.50	-0.51	-1.50	-2.52	-1.96	1.41	1.57	12
Total Operating Income	-1.99	-0.80	-2.94	0.51	0.63	-0.47	-1.48	-1.36	2.46	2.41	13
Total Gross Profit	3.63	5.01	5.63	6.30	6.48	9.86	12	7.86	13	15	25
Total Revenue	7.31	7.97	9.07	10	12	17	19	22	21	24	38
Operating Revenue	7.31	7.97	9.07	10	12	17	19	22	21	24	38
Total Cost of Revenue	3.68	2.96	3.45	4.02	5.17	7.42	7.00	15	8.18	9.53	12
Operating Cost of Revenue	3.68	2.96	3.45	4.02	5.17	7.42	7.00	15	8.18	9.53	12
Total Operating Expenses	5.62	5.81	8.56	5.79	5.85	10	13	9.22	11	12	13
Selling, General & Admin Expense	4.58	5.16	5.59	5.29	6.72	9.17	9.69	8.11	8.86	10	12
Research & Development Expense	1.05	0.65	2.97	0.51	-0.87	1.16	3.71	1.11	1.78	1.88	0.99
Total Other Income / (Expense), net	-0.02	-0.01	-0.05	-0.01	-1.14	-1.03	-1.04	-0.59	-1.05	-0.84	-1.08
Interest & Investment Income	-	-0.01	-0.05	-0.01	-	-1.03	-1.04	-0.59	-	-0.84	-1.08
Income Tax Expense	0.25	0.00	0.05	-0.13	0.09	0.07	0.07	-0.03	-0.07	0.02	0.14
Basic Earnings per Share	($0.10)	($0.03)	($0.12)	$0.02	($0.02)	($0.06)	($0.10)	($0.07)	$0.06	$0.06	$0.42
Weighted Average Basic Shares Outstanding	25.65M	25.76M	25.78M	25.90M	25.90M	26.89M	26.89M	26.89M	26.91M	27.29M	27.64M
Diluted Earnings per Share	-	-	-	$0.02	-	($0.06)	($0.10)	($0.07)	-	$0.05	$0.35
Weighted Average Diluted Shares Outstanding	25.69M	25.69M	25.84M	26.55M	26.82M	26.89M	26.89M	26.89M	27.28M	31.55M	32.79M
Weighted Average Basic & Diluted Shares Outstanding	25.69M	25.69M	25.84M	25.84M	26.82M	26.82M	26.82M	26.82M	27.28M	27.39M	28.58M

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	14	-15	9.23	-6.89	1.90	5.08	-6.45	11
Net Cash From Operating Activities	-8.15	-18	-22	-4.72	4.82	6.82	0.97	11
Net Cash From Continuing Operating Activities	-8.15	-18	-22	-4.72	4.82	6.82	0.97	11
Net Income / (Loss) Continuing Operations	-13	-18	-28	-1.96	-9.02	-0.94	-3.82	-4.60
Consolidated Net Income / (Loss)	-13	-18	-28	-1.96	-9.02	-0.94	-3.82	-4.60
Depreciation Expense	0.06	0.45	0.65	0.46	1.77	0.90	1.15	4.04
Amortization Expense	0.00	0.02	0.12	0.15	0.13	0.12	1.11	0.70
Non-Cash Adjustments To Reconcile Net Income	4.43	1.89	3.84	2.84	5.05	6.04	7.00	14
Changes in Operating Assets and Liabilities, net	0.10	-2.06	1.01	-6.21	6.89	0.70	-4.47	-3.31
Net Cash From Investing Activities	-0.24	-1.85	-0.05	-2.56	-2.79	-0.78	-40	-0.33
Net Cash From Continuing Investing Activities	-0.24	-1.85	-0.05	-2.56	-2.79	-0.78	-40	-0.33
Purchase of Property, Plant & Equipment	-0.24	-1.10	-0.05	-0.01	-0.04	0.00	-0.03	-0.33
Acquisitions	0.00	-0.75	0.00	-3.25	-2.75	-0.78	-40	0.00
Net Cash From Financing Activities	22	5.20	32	0.39	-0.13	-0.96	33	0.82
Net Cash From Continuing Financing Activities	22	5.20	32	0.39	-0.13	-0.96	33	0.82
Repayment of Debt	-	0.00	0.00	-0.15	-0.39	-1.16	-1.16	0.00
Issuance of Debt	0.00	4.75	2.48	-	0.00	0.00	25	0.00
Issuance of Common Equity	23	0.00	29	-	0.17	0.23	7.25	0.22
Other Financing Activities, net	0.00	0.45	0.37	0.54	0.08	-0.03	1.19	0.60
Cash Interest Paid	0.00	0.00	0.80	0.82	0.73	0.84	0.67	3.33
Cash Income Taxes Paid	0.00	0.00	0.00	0.00	0.00	0.25	0.08	0.12

This table details how cash moves in and out of Eton Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-0.68	-4.73	1.04	2.57	-5.33	2.48	7.96	12	-11	-6.28	7.18
Net Cash From Operating Activities	0.39	-2.47	1.26	2.95	-0.77	2.09	7.96	12	-12	7.41	7.26
Net Cash From Continuing Operating Activities	0.32	-2.47	1.26	2.95	-0.77	2.09	7.96	12	-12	7.40	7.26
Net Income / (Loss) Continuing Operations	-2.26	-0.81	-3.04	0.63	-0.60	-1.57	-2.59	-1.93	1.48	1.55	12
Consolidated Net Income / (Loss)	-2.26	-0.81	-3.04	0.63	-0.60	-1.57	-2.59	-1.93	1.48	1.55	12
Depreciation Expense	0.33	0.23	0.26	0.28	0.36	1.01	1.01	1.01	1.02	1.13	1.39
Amortization Expense	0.03	0.03	0.02	0.02	1.04	0.29	0.05	0.18	0.18	0.12	0.16
Non-Cash Adjustments To Reconcile Net Income	1.18	1.46	0.88	5.16	-0.38	8.54	6.60	4.23	-5.57	3.93	2.34
Changes in Operating Assets and Liabilities, net	1.05	-3.38	3.14	-3.13	-1.18	-6.19	2.89	8.54	-8.66	0.67	-8.20
Net Cash From Investing Activities	-0.78	-1.88	-	-	-38	0.00	-	-0.28	-0.05	-15	0.01
Net Cash From Continuing Investing Activities	-0.78	-1.88	-	-	-38	0.00	-	-0.28	-0.05	-15	0.01
Purchase of Property, Plant & Equipment	-	-0.01	-	-	-0.01	0.00	-	-0.28	-0.05	-0.08	0.01
Net Cash From Financing Activities	-0.29	-0.38	-0.22	-0.39	34	0.39	-	-	0.42	1.39	-0.08
Net Cash From Continuing Financing Activities	-0.29	-0.38	-0.22	-0.39	34	0.39	-	-	0.42	1.39	-0.08
Issuance of Common Equity	-	-	-	-	-	0.39	-	-	-0.18	1.39	-1.12
Cash Interest Paid	0.20	0.19	0.17	0.16	0.14	0.64	0.21	1.54	0.93	0.88	0.82
Cash Income Taxes Paid	0.25	0.00	-	0.18	-0.10	0.01	0.08	0.03	0.00	0.04	0.05

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	13	28	17	26	27	25	32	76	92
Total Current Assets	13	28	15	25	24	20	27	41	61
Cash & Equivalents	13	27	12	21	14	16	21	15	26
Accounts Receivable	-	0.00	0.47	0.05	5.47	1.85	3.41	5.36	12
Inventories, net	-	0.00	0.38	1.24	0.55	0.56	0.91	15	15
Prepaid Expenses	0.14	0.77	2.09	2.12	3.18	1.29	1.13	5.49	7.46
Plant, Property, & Equipment, net	0.12	0.77	1.12	0.81	0.12	0.07	0.06	0.03	0.33
Total Noncurrent Assets	0.03	0.05	0.95	0.81	3.75	4.95	4.84	35	31
Intangible Assets	-	0.00	0.73	0.58	3.62	4.75	4.74	35	31
Other Noncurrent Operating Assets	0.03	0.05	0.22	0.23	0.13	0.20	0.10	0.19	0.33
Total Liabilities & Shareholders' Equity	13	28	17	26	27	25	32	76	92
Total Liabilities	1.31	2.02	6.52	11	9.84	12	16	52	66
Total Current Liabilities	0.79	2.02	1.96	3.79	4.56	6.46	16	20	38
Short-Term Debt	-	-	0.00	0.00	1.42	1.03	5.38	0.00	8.79
Accounts Payable	0.54	1.42	0.58	2.34	1.77	1.77	1.85	4.17	11
Accrued Expenses	0.25	0.60	1.39	1.17	1.37	3.66	9.01	16	19
Total Noncurrent Liabilities	0.52	0.00	4.56	6.86	5.28	5.49	0.02	32	27
Long-Term Debt	-	0.00	4.54	6.76	5.26	5.38	0.00	30	22
Other Noncurrent Operating Liabilities	0.52	0.00	0.02	0.10	0.02	0.11	0.02	1.94	5.70
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-6.87	26	11	16	18	13	15	24	26
Total Preferred & Common Equity	-6.87	26	11	16	18	13	15	24	26
Total Common Equity	-6.87	26	11	16	18	13	15	24	26
Common Stock	1.77	72	75	108	112	116	120	132	139
Retained Earnings	-8.64	-46	-64	-92	-94	-103	-104	-108	-112

This table presents Eton Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	24	31	32	31	32	36	84	102	105	98	116
Total Current Assets	19	26	27	24	25	30	50	68	72	53	69
Cash & Equivalents	15	22	22	17	18	20	17	25	37	20	27
Accounts Receivable	2.87	3.08	3.50	4.24	4.87	5.59	16	14	13	13	25
Inventories, net	0.44	0.82	1.05	2.32	2.07	1.94	14	24	17	14	10
Prepaid Expenses	1.10	0.87	0.54	1.05	0.80	1.96	2.52	4.82	4.94	5.71	6.73
Plant, Property, & Equipment, net	0.06	0.05	0.04	0.06	0.05	0.03	0.02	0.02	0.29	0.37	0.35
Total Noncurrent Assets	4.75	4.55	4.33	6.47	6.34	6.06	34	33	32	44	47
Intangible Assets	4.57	4.39	4.21	6.39	6.12	5.85	34	33	32	44	46
Other Noncurrent Operating Assets	0.18	0.16	0.12	0.09	0.22	0.21	0.17	0.34	0.34	0.36	1.18
Total Liabilities & Shareholders' Equity	24	31	32	31	32	36	84	102	105	98	116
Total Liabilities	13	14	15	15	18	20	60	78	81	67	69
Total Current Liabilities	7.49	9.59	10	15	18	20	25	39	44	44	45
Short-Term Debt	1.34	1.54	1.54	5.02	4.66	4.13	-	2.77	2.78	12	8.83
Accounts Payable	1.23	2.30	1.71	2.26	2.13	2.68	4.87	12	14	13	14
Accrued Expenses	4.92	5.75	7.14	8.02	11	13	20	24	27	19	22
Total Noncurrent Liabilities	5.19	4.62	4.24	0.00	0.15	0.13	34	39	37	23	24
Long-Term Debt	5.11	4.55	4.20	-	-	-	30	27	28	19	19
Other Noncurrent Operating Liabilities	0.09	0.07	0.04	0.00	0.15	0.13	4.24	12	9.61	3.98	5.02
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	11	17	17	15	13	16	24	24	23	31	47
Total Preferred & Common Equity	11	17	17	15	13	16	24	24	23	31	47
Total Common Equity	11	17	17	15	13	16	24	24	23	31	47
Common Stock	117	118	119	120	121	123	134	136	137	142	146
Retained Earnings	-106	-101	-102	-105	-108	-107	-109	-112	-114	-111	-99

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	17,607,928.00	17,807,167.00	24,213,533.00	24,606,175.00	-	-	-	26,817,535.00
DEI Adjusted Shares Outstanding	17,607,928.00	17,807,167.00	24,213,533.00	24,606,175.00	-	-	-	26,817,535.00
DEI Earnings Per Adjusted Shares Outstanding	-2.11	-1.03	-1.16	-0.08	-	-	-	-0.17
Growth Metrics	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	-7.22	-13	-19	-1.05	-5.78	-0.83	-1.82	-0.59
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-29.66%	-4.00%	-3.35%	-1.04%
Earnings before Interest and Taxes (EBIT)	-13	-18	-28	-2.32	-9.02	-0.69	-3.81	-4.56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-18	-27	-1.71	-7.12	0.33	-1.55	0.18
Valuation Ratios	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-16	-17	-9.82	0.93	2.89	-42	7.94
Efficiency Ratios	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	-0.43	3.02	1.13	9.90	3.19	-0.53	39	31
Increase / (Decrease) in Invested Capital	0.00	3.46	-1.89	8.77	-6.71	-3.72	40	-8.53
Book Value per Share	$1.49	$0.59	$0.65	$0.72	$0.52	$0.60	$0.95	$0.98
Tangible Book Value per Share	$1.49	$0.55	$0.62	$0.57	$0.33	$0.42	($0.40)	($0.18)
Total Capital	26	15	22	24	19	21	54	57
Total Debt	0.00	4.54	6.76	6.68	6.42	5.38	30	31
Total Long-Term Debt	0.00	4.54	6.76	5.26	5.38	0.00	30	22
Net Debt	-27	-7.53	-15	-7.73	-9.89	-16	15	4.62
Capital Expenditures (CapEx)	0.24	1.10	0.05	-0.69	0.04	0.00	0.03	0.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.26	0.98	-0.39	6.06	-1.73	-5.41	6.14	4.94
Debt-free Net Working Capital (DFNWC)	25	13	21	20	15	16	21	31
Net Working Capital (NWC)	25	13	21	19	14	11	21	22
Net Nonoperating Expense (NNE)	5.52	5.30	8.99	0.91	3.24	0.10	2.01	4.01
Net Nonoperating Obligations (NNO)	-27	-7.53	-15	-7.73	-9.89	-16	15	4.62
Total Depreciation and Amortization (D&A)	0.06	0.46	0.77	0.61	1.90	1.02	2.26	4.74
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.80)	($1.03)	($1.33)	($0.08)	($0.36)	($0.04)	($0.15)	($0.17)
Adjusted Weighted Average Basic Shares Outstanding	17.63M	17.88M	24.41M	24.63M	25.15M	25.65M	25.90M	26.91M
Adjusted Diluted Earnings per Share	($5.80)	($1.03)	($1.33)	($0.08)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	17.63M	17.88M	24.41M	24.63M	25.46M	25.69M	26.82M	27.28M
Adjusted Basic & Diluted Earnings per Share	($5.80)	($1.03)	($1.33)	($0.08)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	6.42M	17.76M	21.01M	25.21M	25.46M	25.69M	26.82M	27.28M
Normalized Net Operating Profit after Tax (NOPAT)	-7.22	-13	-19	-1.05	-5.78	-0.83	-1.82	-0.59
Debt Service Ratios	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Eton Pharmaceuticals' official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	26,817,535.00	26,817,535.00	26,817,535.00	26,817,535.00	27,284,491.00	27,392,358.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	26,817,535.00	26,817,535.00	26,817,535.00	26,817,535.00	27,284,491.00	27,392,358.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-0.06	-0.10	-0.07	0.06	0.06	0.42
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-13.94%	50.19%	-24.36%	46.90%	59.26%	116.95%	108.60%	117.54%	-	40.41%	98.59%
EBITDA Growth	-334.34%	77.18%	-154.25%	346.65%	141.90%	254.71%	83.97%	-121.63%	-	337.63%	3,498.10%
EBIT Growth	-520.96%	68.43%	-162.67%	192.88%	74.59%	41.25%	49.74%	-367.78%	-	613.62%	967.39%
NOPAT Growth	-231.37%	68.43%	-152.91%	266.06%	131.56%	41.25%	49.74%	-249.78%	-	824.42%	1,324.32%
Net Income Growth	-347.37%	69.51%	-166.70%	208.29%	73.49%	-93.83%	15.00%	-407.34%	-	198.86%	547.89%
EPS Growth	0.00%	70.00%	-166.67%	200.00%	0.00%	0.00%	0.00%	-450.00%	-	183.33%	450.00%
Operating Cash Flow Growth	-86.37%	-59.75%	-82.33%	238.14%	-297.67%	184.51%	534.18%	307.38%	-	254.31%	-8.85%
Free Cash Flow Firm Growth	-70.09%	-437.71%	-123.70%	-58.38%	-1,793.70%	-2,225.83%	-2,290.44%	-1,393.93%	-	93.15%	78.75%
Invested Capital Growth	-116.65%	29.54%	-65.97%	-127.73%	7,501.69%	859.37%	6,651.17%	10,662.58%	-	12.64%	65.66%
Revenue Q/Q Growth	4.06%	8.93%	13.91%	13.78%	12.81%	48.38%	9.52%	18.65%	-	14.03%	54.90%
EBITDA Q/Q Growth	-490.85%	73.69%	-406.88%	130.52%	0.37%	3.08%	-150.42%	58.53%	-	0.19%	291.48%
EBIT Q/Q Growth	-317.88%	65.07%	-266.88%	117.34%	-214.34%	19.24%	-213.83%	7.59%	-	-2.03%	429.99%
NOPAT Q/Q Growth	-263.69%	59.86%	-266.88%	131.01%	-30.88%	-174.72%	-213.83%	7.59%	-	-7.77%	430.40%
Net Income Q/Q Growth	-289.64%	64.05%	-274.97%	120.62%	-195.37%	-162.88%	-64.44%	25.45%	-	4.79%	645.05%
EPS Q/Q Growth	0.00%	0.00%	-300.00%	116.67%	0.00%	0.00%	0.00%	0.00%	-	0.00%	600.00%
Operating Cash Flow Q/Q Growth	-55.67%	-739.02%	150.75%	135.22%	-125.91%	373.20%	280.81%	51.10%	-	164.11%	-2.03%
Free Cash Flow Firm Q/Q Growth	-28.35%	-161.91%	14.69%	209.97%	-3,015.87%	14.98%	12.32%	40.47%	-	-120.65%	-171.90%
Invested Capital Q/Q Growth	-194.99%	826.74%	-88.96%	-136.39%	25,456.77%	-5.80%	-22.32%	-43.07%	-	35.52%	14.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	49.64%	62.85%	62.00%	61.04%	55.60%	57.06%	63.00%	34.97%	-	60.72%	67.61%
EBITDA Margin	-26.50%	-6.57%	-29.22%	7.84%	6.97%	4.84%	-2.23%	-0.78%	-	15.10%	38.15%
Operating Margin	-27.25%	-10.04%	-32.35%	4.93%	5.40%	-2.72%	-7.79%	-6.07%	-	9.95%	34.04%
EBIT Margin	-31.31%	-10.04%	-32.35%	4.93%	-5.00%	-2.72%	-7.79%	-6.07%	-	9.95%	34.04%
Profit (Net Income) Margin	-30.85%	-10.18%	-33.51%	6.07%	-5.13%	-9.10%	-13.66%	-8.58%	-	6.40%	30.80%
Tax Burden Percent	112.29%	100.00%	101.81%	125.15%	117.03%	104.94%	102.62%	98.57%	-	98.73%	98.81%
Interest Burden Percent	87.73%	101.38%	101.77%	98.43%	87.80%	318.72%	170.78%	143.43%	-	65.20%	91.59%
Effective Tax Rate	0.00%	0.00%	0.00%	-25.15%	0.00%	0.00%	0.00%	0.00%	-	1.27%	1.19%
Return on Invested Capital (ROIC)	-454.03%	-70.53%	-846.86%	1,059.23%	7.61%	-4.50%	-21.75%	-36.84%	-	21.69%	92.96%
ROIC Less NNEP Spread (ROIC-NNEP)	-447.38%	-68.01%	-839.94%	1,059.29%	190.89%	-269.82%	15.95%	-28.34%	-	14.68%	56.66%
Return on Net Nonoperating Assets (RNNOA)	405.72%	50.62%	793.25%	-1,046.27%	-5.42%	-6.33%	-3.51%	16.59%	-	6.31%	4.70%
Return on Equity (ROE)	-48.31%	-19.92%	-53.61%	12.96%	2.19%	-10.83%	-25.26%	-20.25%	-	28.00%	97.66%
Cash Return on Invested Capital (CROIC)	0.00%	-13.26%	-425.17%	0.00%	-105.98%	-170.01%	-198.03%	-112.40%	-	-8.26%	-6.95%
Operating Return on Assets (OROA)	-34.91%	-12.59%	-32.35%	5.08%	-3.61%	-2.29%	-6.79%	-6.08%	-	9.52%	33.05%
Return on Assets (ROA)	-34.39%	-12.76%	-33.52%	6.25%	-3.71%	-7.66%	-11.90%	-8.60%	-	6.13%	29.91%
Return on Common Equity (ROCE)	-48.31%	-19.92%	-53.61%	12.96%	2.19%	-10.83%	-25.26%	-20.25%	-	28.00%	97.66%
Return on Equity Simple (ROE_SIMPLE)	0.00%	5.89%	-49.67%	-34.30%	0.00%	-18.75%	0.00%	0.00%	-	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.40	-0.56	-2.05	0.64	0.44	-0.33	-1.03	-0.95	2.58	2.38	13
NOPAT Margin	-19.08%	-7.03%	-22.64%	6.17%	3.78%	-1.90%	-5.45%	-4.25%	-	9.82%	33.63%
Net Nonoperating Expense Percent (NNEP)	-6.65%	-2.52%	-6.92%	-0.06%	-183.28%	265.31%	-37.70%	-8.50%	-	7.01%	36.30%
Return On Investment Capital (ROIC_SIMPLE)	-6.69%	-	-	-	0.81%	-0.60%	-1.91%	-1.78%	4.56%	3.88%	16.97%
Cost of Revenue to Revenue	50.36%	37.15%	38.00%	38.96%	44.40%	42.94%	37.00%	65.03%	-	39.28%	32.39%
SG&A Expenses to Revenue	62.57%	64.73%	61.62%	51.22%	57.68%	53.06%	51.18%	36.09%	-	43.05%	30.93%
R&D to Revenue	14.32%	8.17%	32.73%	4.89%	-7.48%	6.72%	19.61%	4.95%	-	7.73%	2.64%
Operating Expenses to Revenue	76.89%	72.90%	94.35%	56.11%	50.20%	59.78%	70.79%	41.04%	-	50.77%	33.57%
Earnings before Interest and Taxes (EBIT)	-2.29	-0.80	-2.94	0.51	-0.58	-0.47	-1.48	-1.36	2.46	2.41	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.94	-0.52	-2.65	0.81	0.81	0.84	-0.42	-0.18	3.66	3.66	14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.26	6.22	6.28	9.70	14.09	14.24	15.95	25.20	-	22.00	21.29
Price to Tangible Book Value (P/TBV)	10.47	10.58	11.52	15.31	0.00	0.00	0.00	0.00	-	0.00	1,093.28
Price to Revenue (P/Rev)	3.55	2.81	2.69	4.47	8.82	7.20	6.57	8.29	-	7.75	9.39
Price to Earnings (P/E)	0.00	105.51	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	78.15
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Earnings Yield	0.00%	0.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	1.28%
Enterprise Value to Invested Capital (EV/IC)	0.00	21.95	167.81	0.00	9.13	9.74	13.45	35.18	-	16.41	20.84
Enterprise Value to Revenue (EV/Rev)	3.05	2.47	2.28	4.01	9.20	7.46	6.65	8.19	-	7.87	9.40
Enterprise Value to EBITDA (EV/EBITDA)	292.94	40.37	0.00	0.00	0.00	348.13	119.17	254.53	-	101.82	46.20
Enterprise Value to EBIT (EV/EBIT)	0.00	81.05	0.00	0.00	0.00	0.00	0.00	0.00	-	335.52	60.87
Enterprise Value to NOPAT (EV/NOPAT)	0.00	198.54	0.00	0.00	0.00	0.00	0.00	0.00	-	479.32	61.17
Enterprise Value to Operating Cash Flow (EV/OCF)	14.14	14.38	1,702.05	65.48	370.50	65.20	31.62	27.03	-	43.21	65.59
Enterprise Value to Free Cash Flow (EV/FCFF)	33.39	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.35	0.32	0.35	0.26	1.22	1.23	1.26	1.31	-	1.00	0.60
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	1.22	1.23	1.14	1.19	-	0.62	0.41
Financial Leverage	-0.91	-0.74	-0.94	-0.99	-0.03	0.02	-0.22	-0.59	-	0.43	0.08
Leverage Ratio	1.99	2.05	2.08	2.05	2.70	2.87	3.57	3.59	-	3.30	3.08
Compound Leverage Factor	1.74	2.08	2.12	2.02	2.37	9.16	6.09	5.15	-	2.15	2.82
Debt to Total Capital	25.79%	24.47%	25.71%	20.52%	54.96%	55.09%	55.74%	56.77%	-	50.11%	37.46%
Short-Term Debt to Total Capital	25.79%	24.47%	25.71%	20.52%	0.00%	0.00%	5.11%	5.19%	-	19.24%	11.85%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	54.96%	55.09%	50.63%	51.58%	-	30.86%	25.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Common Equity to Total Capital	74.21%	75.53%	74.29%	79.48%	45.04%	44.91%	44.26%	43.23%	-	49.89%	62.54%
Debt to EBITDA	16.35	2.39	-0.86	-0.96	-19.20	28.95	9.29	13.42	-	4.57	1.30
Net Debt to EBITDA	-48.66	-5.55	2.40	3.75	-9.58	12.14	1.48	-2.98	-	1.65	0.05
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-19.20	28.95	8.44	12.19	-	2.82	0.89
Debt to NOPAT	-6.45	11.77	-1.06	-1.13	-16.40	-18.90	-53.42	-16.19	-	21.53	1.72
Net Debt to NOPAT	19.19	-27.27	2.97	4.42	-8.18	-7.92	-8.50	3.60	-	7.76	0.07
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-16.40	-18.90	-48.52	-14.71	-	13.26	1.18
Altman Z-Score	0.72	0.39	-1.03	1.84	2.83	2.59	2.28	3.72	-	5.51	8.91
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.65	1.59	1.40	1.51	2.06	1.97	1.77	1.63	-	1.21	1.52
Quick Ratio	1.53	1.37	1.24	1.31	1.02	1.33	1.03	1.14	-	0.75	1.15
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	2.33	-1.44	-1.23	1.35	-39	-33	-29	-17	11	-2.30	-6.24
Operating Cash Flow to CapEx	0.00%	-17,664.29%	0.00%	0.00%	-6,375.00%	0.00%	0.00%	4,234.51%	-	9,873.33%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.11	1.25	1.00	1.03	0.72	0.84	0.87	1.00	-	0.96	0.97
Accounts Receivable Turnover	12.02	9.64	7.89	7.63	8.89	4.68	6.02	7.53	-	5.83	5.37
Inventory Turnover	14.42	8.41	8.82	9.44	1.93	2.52	1.83	3.64	-	2.80	2.62
Fixed Asset Turnover	486.80	607.15	689.69	976.82	848.07	1,223.47	1,847.02	430.07	-	441.29	570.78
Accounts Payable Turnover	5.86	6.63	5.74	6.42	5.19	5.62	3.31	4.04	-	4.28	3.35
Days Sales Outstanding (DSO)	30.36	37.85	46.27	47.82	41.04	77.94	60.62	48.46	-	62.58	67.99
Days Inventory Outstanding (DIO)	25.32	43.41	41.39	38.65	188.85	144.99	199.82	100.28	-	130.37	139.19
Days Payable Outstanding (DPO)	62.33	55.09	63.63	56.85	70.37	64.91	110.31	90.41	-	85.20	108.89
Cash Conversion Cycle (CCC)	-6.66	26.17	24.04	29.62	159.52	158.03	150.13	58.34	-	107.74	98.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.53	3.86	0.43	-0.16	39	37	29	16	31	42	48
Invested Capital Turnover	23.80	10.03	37.40	171.67	2.01	2.36	3.99	8.67	-	2.21	2.76
Increase / (Decrease) in Invested Capital	-3.72	0.88	-0.83	-0.71	40	33	28	17	-8.53	4.68	19
Enterprise Value (EV)	96	85	71	139	359	361	387	576	-	684	993
Market Capitalization	112	96	85	155	344	348	382	583	-	673	992
Book Value per Share	$0.60	$0.60	$0.52	$0.62	$0.95	$0.91	$0.89	$0.86	$0.98	$1.12	$1.70
Tangible Book Value per Share	$0.42	$0.35	$0.29	$0.39	($0.40)	($0.35)	($0.33)	($0.33)	($0.18)	($0.48)	$0.03
Total Capital	21	21	18	20	54	54	54	53	57	61	74
Total Debt	5.38	5.02	4.66	4.13	30	30	30	30	31	31	28
Total Long-Term Debt	0.00	0.00	0.00	0.00	30	30	27	28	22	19	19
Net Debt	-16	-12	-13	-16	15	13	4.80	-6.75	4.62	11	1.06
Capital Expenditures (CapEx)	0.00	0.01	0.00	0.00	0.01	0.00	0.00	0.28	0.05	0.08	-0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.41	-2.67	-5.82	-6.12	6.14	7.19	7.24	-6.53	4.94	1.21	5.46
Debt-free Net Working Capital (DFNWC)	16	14	12	14	21	25	33	31	31	21	32
Net Working Capital (NWC)	11	8.96	7.22	10	21	25	30	28	22	9.07	23
Net Nonoperating Expense (NNE)	0.86	0.25	0.99	0.01	1.04	1.24	1.55	0.97	1.10	0.83	1.06
Net Nonoperating Obligations (NNO)	-16	-12	-13	-16	15	13	4.80	-6.75	4.62	11	1.06
Total Depreciation and Amortization (D&A)	0.35	0.28	0.28	0.30	1.39	1.31	1.05	1.19	1.19	1.25	1.55
Debt-free, Cash-free Net Working Capital to Revenue	-17.10%	-7.79%	-18.54%	-17.65%	15.73%	14.88%	12.44%	-9.28%	-	1.40%	5.17%
Debt-free Net Working Capital to Revenue	50.50%	40.76%	37.84%	40.78%	54.02%	50.92%	56.06%	43.51%	-	24.01%	30.59%
Net Working Capital to Revenue	33.49%	26.13%	23.00%	28.88%	54.02%	50.92%	51.30%	39.56%	-	10.43%	22.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	($0.03)	($0.12)	$0.02	($0.02)	($0.06)	($0.10)	($0.07)	$0.06	$0.06	$0.42
Adjusted Weighted Average Basic Shares Outstanding	25.65M	25.76M	25.78M	25.90K	25.90M	26.89M	26.89M	26.89M	26.91M	27.29M	27.64M
Adjusted Diluted Earnings per Share	$0.00	($0.03)	($0.12)	$0.02	$0.00	$0.00	$0.00	($0.07)	$0.00	$0.05	$0.35
Adjusted Weighted Average Diluted Shares Outstanding	25.69M	25.76M	25.78M	26.55K	26.82M	26.82M	26.82M	26.89M	27.28M	31.55M	32.79M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.69M	25.69M	25.84M	25.84M	26.82M	26.82M	26.82M	26.82M	27.28M	27.39M	28.58M
Normalized Net Operating Profit after Tax (NOPAT)	-1.40	-0.56	-2.05	0.36	0.44	-0.33	-1.03	-0.95	1.72	2.38	13
Normalized NOPAT Margin	-19.08%	-7.03%	-22.64%	3.45%	3.78%	-1.90%	-5.45%	-4.25%	-	9.82%	33.63%
Pre Tax Income Margin	-27.47%	-10.18%	-32.92%	4.85%	-4.39%	-8.67%	-13.31%	-8.70%	-	6.49%	31.17%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Eton Pharmaceuticals (NASDAQ:ETON) has shown a significant improvement in operating performance through the first half of 2026. Revenue reached $37.6 million in Q2 2026, nearly double the $18.9 million reported in Q2 2025 and up from $24.3 million in Q1 2026. The company has progressed from quarterly losses in 2024 and much of 2025 to consecutive quarterly profits in 2026.

Revenue growth has accelerated. Quarterly revenue increased from $7.3 million in Q4 2023 and $11.6 million in Q4 2024 to $21.3 million in Q4 2025 and $37.6 million in Q2 2026. This suggests Eton’s product portfolio and commercial operations are gaining scale.
Profitability improved sharply. Q2 2026 operating income was $12.8 million, compared with operating losses of $1.5 million in Q2 2025 and $2.9 million in Q2 2024. Net income rose to $11.6 million, or $0.42 per basic share, from a $2.6 million loss in the year-ago quarter.
Gross margins strengthened. Q2 2026 gross profit was $25.4 million on $37.6 million of revenue, implying a margin of approximately 67.6%, compared with roughly 63.0% in Q2 2025. Higher-margin products and increased scale appear to be improving profitability.
Operating cash flow remains positive. Eton generated $7.3 million of operating cash flow in Q2 2026 and $7.4 million in Q1 2026, following negative operating cash flow in Q4 2025. This provides support for ongoing operations without relying entirely on external financing.
Liquidity improved during Q2 2026. Cash and equivalents increased to $26.8 million from $19.7 million at the end of Q1. Total current assets rose to $68.6 million, while the current ratio improved to approximately 1.5 from 1.2 in Q1.
Debt levels have declined from 2025. Short- and long-term debt totaled approximately $27.9 million at June 30, 2026, down from $39.2 million at June 30, 2025. Total liabilities also declined as a percentage of assets, while total equity increased to $46.6 million from $24.0 million over the same period.
Acquisitions are an important growth driver. Eton spent $15.0 million on acquisitions in Q1 2026 after spending $38.1 million in Q4 2024. These transactions have contributed to the company’s larger intangible asset base and may support future revenue, but their ultimate returns will depend on successful commercialization.
Accounts receivable increased substantially. Receivables rose to $24.9 million in Q2 2026 from $13.4 million at the end of Q1 and $14.5 million a year earlier. The increase is consistent with higher sales, but it also absorbed working capital and contributed to an $8.2 million negative change in operating assets and liabilities during the quarter.
The balance sheet is increasingly dependent on intangible assets. Intangible assets totaled $45.7 million, or roughly 39% of total assets, at June 30, 2026. This concentration increases the risk of impairment charges if acquired products underperform or expected cash flows do not materialize.
Shareholder dilution remains a consideration. Q2 2026 diluted weighted-average shares rose to 32.8 million versus 26.9 million in Q2 2025, while basic shares were 27.6 million. The difference indicates that options, warrants or other potentially dilutive securities could reduce per-share benefits from future earnings growth.

Overall, the statements show a company transitioning toward a more profitable and cash-generative operating model. Investors should focus on whether the strong 2026 revenue growth can continue, whether receivables convert into cash on a timely basis, and whether acquisitions produce sustainable returns rather than simply expanding the intangible asset balance.

10/10/26 04:09 AM ETAI Generated. May Contain Errors.

Eton Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eton Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Eton Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$4.60 million in 2025, rising from -$12.74 million in 2018. The previous period was -$3.82 million in 2024. Check out Eton Pharmaceuticals' forecast to explore projected trends and price targets.

Eton Pharmaceuticals' total operating income in 2025 was -$844 thousand, based on the following breakdown:

Total Gross Profit: $42.74 million
Total Operating Expenses: $43.58 million

Over the last 7 years, Eton Pharmaceuticals' total revenue changed from $0.00 in 2018 to $79.95 million in 2025, a change of 7,995,000,000.0%.

In the past 13 quarters, Eton Pharmaceuticals' cash and equivalents has ranged from $14.71 million in Q1 2023 to $37.12 million in Q3 2025, and is currently $26.85 million as of their latest financial filing in Q2 2026.

Eton Pharmaceuticals had total debt of $30.56 million at the end of 2025, a 2.5% increase from 2024, and none in 2018.

Over the last 7 years, Eton Pharmaceuticals' book value per share changed from 1.49 in 2018 to 0.98 in 2025, a change of -34.7%.

Related Companies

Financial statements for NASDAQ:ETON last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Financials

Financials Breakdown Chart

Key Financial Trends

Eton Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Financials

Annual Income Statements for Eton Pharmaceuticals

Quarterly Income Statements for Eton Pharmaceuticals

Annual Cash Flow Statements for Eton Pharmaceuticals

Quarterly Cash Flow Statements for Eton Pharmaceuticals

Annual Balance Sheets for Eton Pharmaceuticals

Quarterly Balance Sheets for Eton Pharmaceuticals

Annual Metrics And Ratios for Eton Pharmaceuticals

Quarterly Metrics And Ratios for Eton Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Eton Pharmaceuticals Financials - Frequently Asked Questions

When does Eton Pharmaceuticals' financial year end?

How has Eton Pharmaceuticals' net income changed over the last 7 years?

What is Eton Pharmaceuticals' operating income?

How has Eton Pharmaceuticals' revenue changed over the last 7 years?

How much cash does Eton Pharmaceuticals have?

How much debt does Eton Pharmaceuticals have?

How has Eton Pharmaceuticals' book value per share changed over the last 7 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools